Search Results - "Oscier, David G"

The clinical significance of NOTCH1 and SF3B1 mutations in the UK LRF CLL4 trial by Oscier, David G., Rose-Zerilli, Matthew J.J., Winkelmann, Nils, Gonzalez de Castro, David, Gomez, Belen, Forster, Jade, Parker, Helen, Parker, Anton, Gardiner, Anne, Collins, Andrew, Else, Monica, Cross, Nicholas C.P., Catovsky, Daniel, Strefford, Jonathan C.

“…NOTCH1 and SF3B1 mutations have been previously reported to have prognostic significance in chronic lymphocytic leukemia but to date they have not been…”
Get full text

The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo by Weston, Victoria J., Oldreive, Ceri E., Skowronska, Anna, Oscier, David G., Pratt, Guy, Dyer, Martin J.S., Smith, Graeme, Powell, Judy E., Rudzki, Zbigniew, Kearns, Pamela, Moss, Paul A.H., Taylor, A. Malcolm R., Stankovic, Tatjana

“…The Ataxia Telangiectasia Mutated (ATM) gene is frequently inactivated in lymphoid malignancies such as chronic lymphocytic leukemia (CLL), T-prolymphocytic…”
Get full text

Clinical significance of TP53, BIRC3, ATM and MAPK-ERK genes in chronic lymphocytic leukaemia: data from the randomised UK LRF CLL4 trial by Blakemore, Stuart J., Clifford, Ruth, Parker, Helen, Antoniou, Pavlos, Stec-Dziedzic, Ewa, Larrayoz, Marta, Davis, Zadie, Kadalyayil, Latha, Colins, Andrew, Robbe, Pauline, Vavoulis, Dimitris, Forster, Jade, Carr, Louise, Morilla, Ricardo, Else, Monica, Bryant, Dean, McCarthy, Helen, Walewska, Renata J., Steele, Andrew J., Chan, Jacqueline, Speight, Graham, Stankovic, Tanja, Cragg, Mark S., Catovsky, Daniel, Oscier, David G., Rose-Zerilli, Matthew J. J., Schuh, Anna, Strefford, Jonathan C.

“…Despite advances in chronic lymphocytic leukaemia (CLL) treatment, globally chemotherapy remains a central treatment modality, with chemotherapy trials…”
Get full text

Fc gamma receptor IIb on target B cells promotes rituximab internalization and reduces clinical efficacy by Lim, Sean H., Vaughan, Andrew T., Ashton-Key, Margaret, Williams, Emily L., Dixon, Sandra V., Chan, H. T. Claude, Beers, Stephen A., French, Ruth R., Cox, Kerry L., Davies, Andrew J., Potter, Kathleen N., Mockridge, C. Ian, Oscier, David G., Johnson, Peter W.M., Cragg, Mark S., Glennie, Martin J.

“…The anti-CD20 mAb rituximab is central to the treatment of B-cell malignancies, but resistance remains a significant problem. We recently reported that…”
Get full text

Whole exome sequencing identifies novel recurrently mutated genes in patients with splenic marginal zone lymphoma by Parry, Marina, Rose-Zerilli, Matthew J J, Gibson, Jane, Ennis, Sarah, Walewska, Renata, Forster, Jade, Parker, Helen, Davis, Zadie, Gardiner, Anne, Collins, Andrew, Oscier, David G, Strefford, Jonathan C

“…The pathogenesis of splenic marginal zone lymphoma (SMZL) remains largely unknown. Recent high-throughput sequencing studies have identified recurrent…”
Get full text

ATM mutation rather than BIRC3 deletion and/or mutation predicts reduced survival in 11q-deleted chronic lymphocytic leukemia: data from the UK LRF CLL4 trial by Rose-Zerilli, Matthew J J, Forster, Jade, Parker, Helen, Parker, Anton, Rodríguez, Ana E, Chaplin, Tracy, Gardiner, Anne, Steele, Andrew J, Collins, Andrew, Young, Bryan D, Skowronska, Anna, Catovsky, Daniel, Stankovic, Tatjana, Oscier, David G, Strefford, Jonathan C

“…ATM mutation and BIRC3 deletion and/or mutation have independently been shown to have prognostic significance in chronic lymphocytic leukemia. However, the…”
Get full text

The genomic and molecular landscape of splenic marginal zone lymphoma, biological and clinical implications by Mirandari, Amatta, Parker, Helen, Ashton-Key, Margaret, Stevens, Benjamin, Walewska, Renata, Stamatopoulos, Kostas, Bryant, Dean, Oscier, David G, Gibson, Jane, Strefford, Jonathan C

“…Splenic marginal zone lymphoma (SMZL) is a rare, predominantly indolent B-cell lymphoma constituting fewer than 2% of lymphoid neoplasms. However, around 30%…”
Get full text

Inactivation of HOXA Genes by Hypermethylation in Myeloid and Lymphoid Malignancy is Frequent and Associated with Poor Prognosis by STRATHDEE, Gordon, HOLYOAKE, Tessa L, JORGENSEN, Heather G, SOUTAR, Richard, BROWN, Robert, SIM, Alyson, PARKER, Anton, OSCIER, David G, MELO, Junia V, MEYER, Stefan, EDEN, Tim, DICKINSON, Anne M, MOUNTFORD, Joanne C

“…Purpose: The HOX genes comprise a large family of homeodomain-containing transcription factors, present in four separate clusters, which are key regulators of…”
Get full text

Low frequency mutations independently predict poor treatment-free survival in early stage chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis by Winkelmann, Nils, Rose-Zerilli, Matthew, Forster, Jade, Parry, Marina, Parker, Anton, Gardiner, Anne, Davies, Zadie, Steele, Andrew J, Parker, Helen, Cross, Nicholas C P, Oscier, David G, Strefford, Jonathan C

Get full text

ATM germline heterozygosity does not play a role in chronic lymphocytic leukemia initiation but influences rapid disease progression through loss of the remaining ATM allele by SKOWRONSKA, Anna, AUSTEN, Belinda, TAYLOR, Malcolm A, STANKOVIC, Tatjana, POWELL, Judith E, WESTON, Victoria, OSCIER, David G, DYER, Martin J. S, MATUTES, Estella, PRATT, Guy, FEGAN, Christopher, MOSS, Paul

“…Ataxia telangiectasia patients, with constitutional bi-allelic ATM mutations, have a marked risk of lymphoid tumors and ATM mutation carriers have a smaller…”
Get full text

The BCL11 gene family: involvement of BCL11A in lymphoid malignancies by Satterwhite, Ed, Sonoki, Takashi, Willis, Tony G., Harder, Lana, Nowak, Rachael, Arriola, Emma L., Liu, Hui, Price, Helen P., Gesk, Stefan, Steinemann, Doris, Schlegelberger, Brigitte, Oscier, David G., Siebert, Reiner, Tucker, Philip W., Dyer, Martin J.S.

“…Many malignancies of mature B cells are characterized by chromosomal translocations involving the immunoglobulin heavy chain(IGH) locus on chromosome 14q32.3…”
Get full text

Methylation markers identify high risk patients in IGHV mutated chronic lymphocytic leukemia by Irving, Laura, Mainou-Fowler, Tryfonia, Parker, Anton, Ibbotson, Rachel E, Oscier, David G, Strathdee, Gordon

“…Chronic lymphocytic leukemia (CLL) exhibits a very variable clinical course. Altered DNA methylation of genes has shown promise as a source of novel prognostic…”
Get full text

CBL-MZ is not a single biological entity: evidence from genomic analysis and prolonged clinical follow-up by Parker, Helen, McIver-Brown, Neil Robert, Davis, Zadie A., Parry, Marina, Rose-Zerilli, Matthew J.J., Xochelli, Aliki, Gibson, Jane, Walewska, Renata, Strefford, Jonathan C., Oscier, David G.

“…[Display omitted]…”
Get full text

Association between single nucleotide polymorphism-genotype and outcome of patients with chronic lymphocytic leukemia in a randomized chemotherapy trial by WADE, Rachel, BERNARDO, Maria Chiara Di, RICHARDS, Sue, ROSSI, Davide, CROWTHER-SWANEPOEL, Dalemari, GAIDANO, Gianluca, OSCIER, David G, CATOVSKY, Daniel, HOULSTON, Richard S

“…There is variability in the outcome of patients with chronic lymphocytic leukemia with apparently the same stage of disease. Identifying genetic variants that…”
Get full text

A unique genome in EBV-positive BL by Strefford, Jonathan C., Oscier, David G.

Get full text

Telomere length and DNA methylation epitype both provide independent prognostic information in CLL patients; data from the UK CLL4, ARCTIC and ADMIRE clinical trials by Carr, Louise, Norris, Kevin, Parker, Helen, Nilsson-Takeuchi, Anna, Bryant, Dean, Amarasinghe, Harindra, Kadalayil, Latha, Else, Monica, Pettitt, Andrew, Hillmen, Peter, Schuh, Anna, Walewska, Renata, Baird, Duncan M, Oscier, David G, Oakes, Christopher C, Gibson, Jane, Pepper, Chris, Strefford, Jonathan C

Get full text

Rituximab Plus Chlorambucil As First-Line Treatment for Chronic Lymphocytic Leukemia: Final Analysis of an Open-Label Phase II Study by HILLMEN, Peter, GRIBBEN, John G, NATHWANI, Amit, VARGHESE, Abraham, COHEN, Dena, RAWSTRON, Andy, OERTEL, Stephan, POCOCK, Christopher F. E, FOLLOWS, George A, MILLIGAN, Donald, SAYALA, Hazem A, MORETON, Paul, OSCIER, David G, DEARDEN, Claire E, KENNEDY, Daniel B, PETTITT, Andrew R

“…Most patients with chronic lymphocytic leukemia (CLL) are elderly and/or have comorbidities that may make them ineligible for fludarabine-based treatment. For…”
Get full text

ZAP-70 expression and prognosis in chronic lymphocytic leukaemia by Orchard, Jenny A, Ibbotson, Rachel E, Davis, Zadie, Wiestner, Adrian, Rosenwald, Andreas, Thomas, Peter W, Hamblin, Terry J, Staudt, Louis M, Oscier, David G

“…Chronic lymphocytic leukaemia (CLL) is a heterogeneous disease; many patients never need treatment, whereas some have poor outcomes. New treatments, which can…”
Get full text

DLEU2 encodes an antisense RNA for the putative bicistronic RFP2/LEU5 gene in humans and mouse by Corcoran, Martin M., Hammarsund, Marianne, Zhu, Chaoyong, Lerner, Mikael, Kapanadze, Bagrat, Wilson, Bill, Larsson, Catharina, Forsberg, Lars, Ibbotson, Rachel E., Einhorn, Stefan, Oscier, David G., Grandér, Dan, Sangfelt, Olle

“…Our group previously identified two novel genes, RFP2/LEU5 and DLEU2, within a 13q14.3 genomic region of loss seen in various malignancies. However, no…”
Get full text

Chronic lymphocytic leukemia cells recognize conserved epitopes associated with apoptosis and oxidation by Catera, Rosa, Silverman, Gregg J, Hatzi, Katerina, Seiler, Till, Didier, Sebastien, Zhang, Lu, Hervé, Maxime, Meffre, Eric, Oscier, David G, Vlassara, Helen, Scofield, R Hal, Chen, Yifang, Allen, Steven L, Kolitz, Jonathan, Rai, Kanti R, Chu, Charles C, Chiorazzi, Nicholas

“…Chronic lymphocytic leukemia (CLL) represents the outgrowth of a CD5(+) B cell. Its etiology is unknown. The structure of membrane Ig on CLL cells of unrelated…”
Get full text